Saturday, December 5, 2015, 7:30-11:00 AM

7:30-9:00 AM

Educational Session: Challenging Scenarios in Thrombosis
W311, Level 3 (Orange County Convention Center)
CHAIR: Sarah O’Brien, MD
SPEAKERS: Sarah O’Brien, MD, Perinatal Thrombosis: Implications for Mother and Neonate
Keith R. McCrae, MD, The Antiphospholipid Syndrome: Still an Enigma
Lisa M. Baumann Kreuziger, MD, BloodCenter of Wisconsin
Mechanical Circulatory Support: Balancing Bleeding and Clotting in High-Risk Patients

9:30-11:00 AM

Educational Session: Optimizing Therapy in Sickle Cell Disease
Chapin Theater (W320), Level 3 (Orange County Convention Center)
CHAIR: Griffin P. Rodgers, MD
SPEAKERS: Sophie Lanzkron, MD The Five Key Things You Need to Know to Manage Adult Patients with Sickle Cell Disease
Russell E. Ware, MD, PhD Optimizing Hydroxyurea Therapy in Sickle Cell Disease
Joshua Field, MD, BloodCenter of Wisconsin
Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease?

Saturday, December 5, 2015, 5:30-7:30 PM

Hall A, Level 2 (Orange County Convention Center)
Poster I
Session: 301. Platelet Activation and Biochemistry

1053 - Genetic Evaluation in aHUS: Characterization of a Variant of Unknown Significance in CFHR3 Disorders of Platelet Number or Function
Valerie Trapp-Stamborski, PhD, Stefanie N Dugan, MS, CGC, Kenneth D Friedman, MD, Matthew Anderson, MD and Rupa A Udani, Ph

1063 - Structural Basis for Quinine-Dependent Antibody Binding to Platelet Integrin alphabeta3
Disorders of Platelet Number or Function
Jianghai Zhu, PhD1,2, Jieqing Zhu, PhD, Daniel W. Bougie, PhD, Richard H. Aster, MD and Timothy A. Springer, PhD

Session: 301. Blood Coagulation and Fibrinolytic Factors; Poster Session I

1067 - The Impact of GPIba on the Efficacy of Platelet-Targeted FVIII Gene Therapy in Hemophilia a with Pre Existing Anti-FVIII Immunity Blood Coagulation and Fibrinolytic Factors
Juan Chen, PhD, Jocelyn Schroeder, Xiaofeng Luo, MD, Robert R Montgomery, MD and Qizhen Shi, MD, PhD

1071 - Immune Tolerance Developed in Platelet-Targeted FVIII Gene Therapy in Hemophilia Mice Is CD4+ T Cell-Mediated Blood Coagulation and Fibrinolytic Factors
Yingyu Chen, PhD1,2, Xiaofeng Luo, MD,1,2, Juan Chen, PhD, Jocelyn Schroeder*, Christina K Baumgartner, PhD1, Jianda Hu, MD, PhD and Qizhen Shi, MD, PhD

Saturday, December 5, 2015, 7:30 – 11:00 AM

Educational Session: Challenging Scenarios in Thrombosis
W224, Level 2 (Orange County Convention Center)
CHAIR: Sarah O’Brien, MD
SPEAKERS: Sarah O’Brien, MD, Perinatal Thrombosis: Implications for Mother and Neonate
Keith R. McCrae, MD, The Antiphospholipid Syndrome: Still an Enigma
Lisa M. Baumann Kreuziger, MD, BloodCenter of Wisconsin
Mechanical Circulatory Support: Balancing Bleeding and Clotting in High-Risk Patients
**Sunday, December 6, 2015: 9:30 – 11:00 AM**

**Educational Session:** Optimizing Therapy in Sickle Cell Disease

**Hall E1, Level 2 (Orange County Convention Center)**

**CHAIR:** Griffin P. Rodgers, MD

**SPEAKERS:** Sophie Lanckron, MD *The Five Key Things You Need to Know to Manage Adult Patients with Sickle Cell Disease*

Russell E. Ware, MD, PhD *Optimizing Hydroxyurea Therapy in Sickle Cell Disease*

Joshua Field, MD, BloodCenter of Wisconsin *Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease?*

---

**Sunday, December 6, 2015**

**Oral Abstract Presentations**

**Session: 321. Blood Coagulation and Fibrinolytic Factors: Coagulation Proteins and Blood Vessels**

**9:30 AM**

W314, Level 3 (Orange County Convention Center)

**211 - Bleeding Phenotype Observed in Murine Defect of VWF-Collegen 4 Interactions**

Blood Coagulation and Fibrinolytic Factors

Veronica H Flood, MD*, Tricia L Slobodianuk*, Ashley Doruelo*, Derek Adams*, Jamie Foeckler*, Shawn Kolloway*, Hartmut Weiller* and Robert R Montgomery*

Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Novel Immunodeficiencies and Natural Killer Cell Biology

---

**10:15 AM**

W315, Level 3 (Orange County Convention Center)

**208 - Impact of Kindlin-3 in NK Cell-Mediated Anti-Tumor Cytotoxicity and Inflammatory Cytokine Production**

Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections

Nathan J. Schloemer, MD, PhD*, Alex M Abel, MS, PhD, Monica S Thakar, MD*, Yan-Qing Ma, PhD* and Subramaniam Malarkannan, PhD*

Session: 321. Blood Coagulation and Fibrinolytic Factors: Coagulation Proteins and Blood Vessels

---

**10:45 AM**

W314, Level 3 (Orange County Convention Center)

**216 - Coagulation Factor V Mediates Inhibition of TissueFactor Signaling By Activated Protein C Blood Coagulation and Fibrinolytic Factors**

Hartmut Weiller*, Hai-Po Liang, PhD*, Edward J Kerschen, PhD*, Alireza Rezaei, PhD*, Jose A. Fernandez, MD, PhD*, Rodney M. Camire, PhD*, Wolfram Ruf, MD*, John H. Griffin, PhD* and Raffaele Tosel, PhD*

Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: T and B Lymphocyte Biology

---

**4:45 PM**

W315, Level 3 (Orange County Convention Center)

**284 - Kras Is Critical for CD8 T Cell Antiviral Function**

Yuhong Chen, Ph.D.*, Yongwei Zheng, Ph.D.*, Xiaona You, Ph.D.*, Gang Xin, Ph.D.*, Mei Yu, Ph.D.*, Guoping Fu, Ph.D.*, Fen Zhou*, Wen Zhu*, Weigu Cui, Ph.D.*, Jing Zhang, PhD*, Renren Wen, PhD* and Demin Wang, PhD*

---

**Sunday, December 6, 2015: 6:00-8:00 PM**

**Hall A, Level 2 (Orange County Convention Center)**

**Poster II**

**Session:** 114. Hemoglobinopathies, Excluding Thalassemia – Clinical

**2178 - NKT120 Safely Depletes INKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial**

- Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease?
  - Joshua J. Field, MD, MS*, Elaine M. Majerus, MD, PhD*, Ken I. Ataga, MD*, Elliott P. Vichinsky, MD, Cheryl Eaton*, Rosemary Mazanet, MD, PhD* and David G. Nathan, MD, PhD*

Session: 311. Disorders of Platelet Number or Function

---

**2246 - Binding of Quinine-Dependent Monoclonal Antibodies to Gpilb/ilia Appears to Involve Drug-Induced Modulation of Antibody Affinity Disorders of Platelet Number or Function**

Daniel W. Bougie, PhD, Julie A. Peterson, PhD, Mark Rasmussen and Richard H. Aster, MD

Session: 321. Blood Coagulation and Fibrinolytic Factors

---

**2264 - Targeting FVIII Expression to Platelets for Hemophilia A Gene Therapy Does Not Bare an Apparent Thrombosis Risk load Coagulation and Fibrinolytic Factors**

Christina K Baumgartner, PhD*, Jeremy G Mattson*, Hartmut Weiller, Qizhen Shi and Robert R Montgomery

---

**2265 - Generation and Initial Characterization of Three Murine Models with Altered Platelet TFPI Expression Blood Coagulation and Fibrinolytic Factors**

Nicholas D. Martinez, BS*, Susan A Maroney, DVM, PhD*, Julie A. Peterson, PhD*, Wes Zwiefelhofer, BS*, Sinny Delacroix, MD*, Shuchong Pan, MD, PhD*, Robert Simari, MD* and Alan E. Mast, MD, PhD*

Session: 322. Disorders of Coagulation or Fibrinolysis

---

**2289 - Non- Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a Disorders of Coagulation or Fibrinolysis**

Beth Boudien Warren, MD, MS*, Linda Jacobsen, BS**, Elizabeth Villalobos-Menuey, BS**, Thomas C. Abshire, MD*, Amy D Shapiro, MD*, Michael Recht, MD, PhD*, Deborah Brown, MD*, Cindy A. Leissinger, MD*, Christine L. Kempton, MD, MSC*, Heidi Lane, PT, DPT, PCS**, Diane J. Nugent, MD** and Marilyn J. Manco-Johnson, MD**
Sunday, December 6, 2015, 6:00-8:00 PM
Hall A, Level 2 (Orange County Convention Center)
Poster II

2293 - Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease
Disorders of Coagulation or Fibrinolysis
Margaret V Ragni1*, Giancarlo Castaño1, Joan Cox Gill1,6, Peter Koudies2,3, Miranda Chapman2, Arthur Sytkowski2,7, Ottrun Obermann-Slupetzky5, Isabella Presch5, Sandor Fritsch7 and Bruce M. Ewenstei

Session: 401. Basic Science and Clinical Practice in Blood Transfusion

2340 - Involvement of the EGF Domain in the Formation of the Human Platelet Alloantigen, HPA-1a
Huiying Zhi, MD, PhD, Panida Lertkiatmongkol1, Brian R Curtis, PhD, D(ABMLI) and Peter J. Newman, PhD

2341 - Crisp/Cas9-Mediated Generation of Mouse Platelets Expressing the Human Platelet Alloantigen, HPA-1a
Huiying Zhi, MD, PhD, Nanyan Zhang, MD, PhD, Jamie Foeckler, Shawn Kalloway, PhD, Sridhar Rao, MD, PhD, Brian R Curtis, PhD, D(ABMLI), Hartmut Weiler, PhD and Peter J. Newman, PhD

Monday, December 7, 2015
Oral Abstract Presentations

Session: 321. Blood Coagulation and Fibrinolytic Factors: Coagulation Proteins in Development and Disease

7:15 AM
W314, Level 3 (Orange County Convention Center)

422 - Hyperactivatable Protein C Expression Partially Rescues the Embryonic Lethality of TFPI Null Mice but Surviving Mice Develop Severe Hydrocephalus
Susan A Maroney, DVM, PhD1, Paul Ellery, PhD1, Nicholas D. Martinez, BS1, Mark Zogg, BS2, Hartmut Weiler1 and Alan E. Mast, MD, PhD1

7:30 AM
W314, Level 3 (Orange County Convention Center)

423 - TFPIa Has Reduced Ability to Inhibit FV Leiden
Jeremy P. Wood, PhD1, Lisa Baumann Kreuziger, MD1, Rodney M. Camire, PhD1 and Alan E. Mast, MD, PhD1

8:00 AM
W314, Level 3 (Orange County Convention Center)

425 - Genetic Absence of Thrombin Receptor Par4 Overcomes the Obligate Requirement of EPCR in Mouse Placenta
Michelle M Storage, BS1, Jianzhong An, MD1, Helena Liang1, Qiuhui Yang, MD, PhD1, Mark Zogg, BS2, Min Zhan, MS1, Hartmut Weiler1 and Rashmi Sood, PhD1

Session: 322. Disorders of Coagulation or Fibrinolysis: Clinical Aspects of Bleeding Disorders

4:45 PM
W314, Level 3 (Orange County Convention Center)

758 - Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program Disorders of Coagulation or Fibrinolysis
Pamela A Christopherson1, Veronica H Flood, MD2, Sandra L Haberichter, PhD3, Daniel B Bellissimo, PhD3, Kenneth D Friedman, MD4, Joan Cox Gill, MD5, Rupa A Udani, PhD6, Robert R Montgomery, MD7 and Zimmerman Program Investigators8

Session: 331. Pathophysiology of Thrombosis: Procoagulant States – Assessment and Risks

4:45 PM
W311ABCD, Level 3 (Orange County Convention Center)

764 - A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis (HIT)
Anand Padmanabhan, MBBS, MA, PhD, Curtis Jones2, Brian R Curtis, MS, MT(ASCP)SBB3, Daniel W. Bougie, PhD4, Mia Sullivan5, Namrata Peswani, MD, MBBS6, Janice McFarland, MD7, Daniel Eastwood8, Demin Wang, PhD2 and Richard H. Aster, MD9

Session: 322. Disorders of Coagulation or Fibrinolysis: Clinical Aspects of Bleeding Disorders

5:30 PM
W314, Level 3 (Orange County Convention Center)

761 - A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population
Suman L. Sood, MD1, Dunlei Cheng, PhD2, Margaret V Ragni3, Craig M. Kessler, MD4, Doris Quon, MD5, Amy D Shapiro, MD6, Nigel S. Key, MBCM6, Marilyn J. Manco-Johnson, MD7, Adam Cuker, MD8, Christine Kempton, MD9, Tzu-Fei Wang, MD10, M. Elaine Eyster, MD11, Philip Kuriakose, MD12, Annette von Drygalski, MD, PharmD13, Joan Cox Gill, MD14, Allison Paroskie, MD15, Peter A. Koudes16, Miguel Antonio Escobar, MD16, Cindy A. Leissinger, MD17, Sarah Galdzicka18, Diane Aschman19 and Barbara Konkle, MD20

Monday, December 7, 2015, 6:00-8:00 PM
Hall A, Level 2 (Orange County Convention Center)
Poster III

Session: 302. Vascular Wall Biology, Endothelial Progenitor Cells and Platelet Adhesion

3450 - Species-Specific Roles for a2-3- and a2-6-Linked Sialic Acid Residues in PECAM-1-Mediated Homophilic Interactions
Panida Lertkiatmongkol, MSc1,2, Cathy Paddock1 and Peter J. Newman, PhD2
Monday, December 7, 2015, 6:00-8:00 PM  
Hall A, Level 2 (Orange County Convention Center)  
Poster III

Session: 302. Vascular Wall Biology, Endothelial Progenitor Cells and Platelet Adhesion

3453 Structure and Sequence Diversity of the Membrane Distal Region of α-Cytoplasmic Tail in Integrin Activation  
Aye Myat Myat Thinn1,2* and Jieqing Zhu, PhD1,2

Session: 321. Blood Coagulation and Fibrinolytic Factors

3485 - Engineering a Valve-Regulated Endothelialized Microfluidic Device As an “In Vitro” Bleeding Time for Assessing Global Hemostasis Blood Coagulation and Fibrinolytic Factors  
Yumiko Sakurai, MSc1,2, Elaissa T. Hardy, PhD1,2*, Byungwook Ahn, PhD1,2, Shannon L. Meeks, MD3, W. Hunter Baldwin, BS4, Shawn M Jobe, MD, PhD5 and Wilbur A Lam, MD, PhD1,2

Session: 504. Hematopoiesis: Cytokines, Signal Transduction, Apoptosis and Cell Cycle Regulation

3588 - Kras Is Critical for B Cell Lymphopoiesis  
Yongwei Zheng, Ph.D.1, Yuhong Chen, Ph.D.2, Xiaona You, Ph.D.3*, Mel Yu, Ph.D.3, Guoping Fu, Ph.D.4*, Xinlin Su4, Wen Zhu4, Zhihong Wu5, Jing Zhang, Ph.D.6, Renren Wen, PhD7 and Demin Wang, PhD unfavorable

Session: 506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion and Stromal Stem Cells

3596 - Physiologic Hematopoiesis Is Dependent on Stromal Expression of Laminin-111  
Sreemanti Basu, PhD1, Irene Hernandez, MS1, Mark Zogg, BS1, Hartmut Weiler, Ph.D.2, Karen-Sue B. Carlson, MD, PhD3 and Pouneh Kermani, PhD4

Session: 801. Gene Therapy and Transfer

4423 - Platelet-Targeted Gene Transfer Induces Immune Tolerance through Two Distinct Pathways  
Xiaofeng Luo, MD1,2, Juan Chen, PhD3, Jocelyn Schroeder3, Christina K Baumgartner, PhD3, Jianda Hu, MD, PhD4 and Qizhen Shi, MD, PhD5